Skip to main content

Table 3 Th e National eye institute 39-question visual function questionnaire scores analyzed by disease category

From: Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis

  Category 1 Category 2 Category 3
Mean P value Mean P value Mean P value
VFQ-25 subscales BL
( n= 7)
M6
( n= 7)
M12
( n= 4)
BL-M6 BL-M12 BL
( n= 11)
M6
( n= 11)
M12
( n= 11)
BL-M6 BL-M12 BL
( n= 8)
M6
( n= 8)
M12
( n= 8)
BL-M6 BL-M12
General health 73.98 73.47 73.21 0.93 0.39 76.62 75.32 74.03 0.73 0.44 56.25 65.18 67.41 0.26 0.11
General vision 50.48 58.57 70.00 0.38 0.08 66.06 76.36 73.33 0.03 0.27 67.50 72.50 70.42 0.14 0.65
Ocular pain 64.29 78.57 78.13 0.10 0.04 80.68 87.50 94.32 0.14 0.001 70.31 78.13 79.69 0.43 0.27
Near activities 54.52 57.98 63.33 0.66 0.12 73.48 76.89 79.17 0.23 0.16 78.65 75.00 75.00 0.49 0.30
Distance activities 64.76 69.35 71.88 0.52 0.06 77.27 84.09 82.58 0.01 0.29 77.08 82.81 84.27 0.36 0.18
Vision-specific social functioning 79.76 84.52 83.33 0.52 0.10 87.12 94.70 96.21 0.10 0.07 94.79 92.71 96.35 0.68 0.55
Vision-specific mental health 34.76 47.14 51.25 0.16 0.05 64.09 73.18 81.36 0.07 0.02 74.69 83.75 81.88 0.02 0.30
Vision-specific role difficulties 47.32 52.68 64.06 0.36 0.11 80.11 85.80 89.20 0.22 0.19 78.13 83.59 83.59 0.41 0.33
Vision-specific dependency 66.96 74.11 75.00 0.31 0.10 82.39 88.64 94.89 0.27 0.13 97.66 99.22 98.44 0.45 0.60
Driving 56.55 55.56 47.22 1.00 0.42 81.48 74.24 78.03 0.36 0.49 65.48 84.72 83.33 0.03 0.08
Color vision 85.71 92.86 93.75 0.46 0.18 88.64 95.45 93.18 0.39 0.44 96.88 96.88 96.88 NS NS
Peripheral vision 75.00 82.14 75.00 0.57 0.64 84.09 87.50 84.09 0.57 1.00 75.00 76.56 75.00 0.83 1.00
Composite score for VFQ-39 (VFQ-25 + additional items) 61.83 68.70 71.09 0.21 0.03 78.18 84.03 86.03 0.03 0.08 79.78 84.04 84.13 0.15 0.09
  1. Italicized values indicate statistical significance.
  2. BL, baseline; M6, month 6; M12, month 12, VFQ, Visual Function Questionnaire, Category 1, active uveitis and receiving no treatment; Category 2, active uveitis and receiving ≥10 mg/day of prednisone and/or at least one other systemic immunosuppressant; Category 3, inactive uveitis and receiving <10 mg/day of prednisone and/or at least one other systemic immunosuppressant.